0000950170-24-015557.txt : 20240214
0000950170-24-015557.hdr.sgml : 20240214
20240214205345
ACCESSION NUMBER: 0000950170-24-015557
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shetzline Michael
CENTRAL INDEX KEY: 0001808509
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 24641714
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2024-02-12
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001808509
Shetzline Michael
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
false
true
false
false
CMO,SVP,Head-Res&Drug
false
Class A Common Stock
2024-02-12
4
S
false
38618
15.24
D
340484
D
Class A Common Stock
2024-02-12
4
A
false
54427
0
A
394911
D
Performance-based Restricted Stock Unit
2024-02-12
4
A
false
27214
0
A
2027-02-28
Class A Common Stock
27214
27214
D
The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share.
/s/ Brian Tessler, Attorney-in-Fact
2024-02-14